Skip to content

Study · Systematic review · 2026

4 results

Efficacy and safety of anti-prediabetic drugs in patients with prediabetes: a Bayesian network meta-analysis.

Wu Y, Wang Z, Tuersun A, Yu Q, Zhong Y, Ali SSA, Liu H, Hu X, Zhang Y, Pang L, Li L, Gao L and 8 more

Show all authors

Wu Q, Wang S, Cui M, Sun L, Wu Y, Yin A, Zhang L, Ma G

BMC medicine19 Feb 2026

PMID41715123 (opens in a new tab)PMCIDPMC13020221 (opens in a new tab)DOI10.1186/s12916-026-04705-2 (opens in a new tab)PepBankPUB-41715123
Read at sourcePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In adults with prediabetes, network meta-analysis found that semaglutide 2.4 mg SC gave the largest weight loss of the interventions (MD -13.59 kg versus placebo).

    In plain wordsIn adults with prediabetes, semaglutide 2.4 mg injections led to the biggest weight loss among the drugs compared, more than placebo.

    Peptide
    Semaglutide
    Outcome
    DecreaseWeight loss (mean difference)
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    2.4 mg · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    2.4 mg of semaglutide SC demonstrated the most optimal efficacy in WL (MD - 13.59 kg; 95% confidence interval (CI) - 17.30 to - 9.91)
    2 context sentences
    Summary · context
    Eligible randomized controlled trials (RCTs) enrolled adults with prediabetes, compared the efficacy and safety of placebo and anti-prediabetic drugs (e.g., metformin, sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide-1 receptor agonists, and thiazolidinedione) with a follow-up durati…
    Summary · context
    Fifty-five eligible RCTs involving 37 interventions with 16,610 participants were included in this study.
  2. 02HumanSystematic reviewEfficacy outcome

    In adults with prediabetes, semaglutide 2.4 mg SC lowered HbA1c versus placebo (MD -0.39%).

    In plain wordsIn adults with prediabetes, semaglutide 2.4 mg injections lowered blood sugar markers (HbA1c) more than placebo.

    Peptide
    Semaglutide
    Outcome
    DecreaseHbA1c change (mean difference)
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    2.4 mg · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    2.4 mg of semaglutide SC demonstrated the most optimal efficacy in WL (MD - 13.59 kg; 95% confidence interval (CI) - 17.30 to - 9.91) and favorable efficacy in lowering HbA1c (MD - 0.39%; 95% CI - 0.55 to - 0.25)
    2 context sentences
    Summary · context
    Eligible randomized controlled trials (RCTs) enrolled adults with prediabetes, compared the efficacy and safety of placebo and anti-prediabetic drugs (e.g., metformin, sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide-1 receptor agonists, and thiazolidinedione) with a follow-up durati…
    Summary · context
    Fifty-five eligible RCTs involving 37 interventions with 16,610 participants were included in this study.
  3. 03HumanSystematic reviewEfficacy outcome

    In adults with prediabetes, tirzepatide 15 mg significantly lowered fasting plasma glucose versus placebo (MD -9.58 mg/dL).

    In plain wordsIn adults with prediabetes, tirzepatide 15 mg lowered fasting blood sugar more than placebo.

    Peptide
    Tirzepatide
    Outcome
    DecreaseFasting plasma glucose (mean difference)
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    15 mgAs given in this study (human).

    Source sentences

    Summary
    15 mg of tirzepatide showed significant efficacy in lowering FPG (MD - 9.58 mg/dL; 95% CI - 12.00 to - 7.15)
    2 context sentences
    Summary · context
    Eligible randomized controlled trials (RCTs) enrolled adults with prediabetes, compared the efficacy and safety of placebo and anti-prediabetic drugs (e.g., metformin, sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide-1 receptor agonists, and thiazolidinedione) with a follow-up durati…
    Summary · context
    Fifty-five eligible RCTs involving 37 interventions with 16,610 participants were included in this study.
  4. 04HumanSystematic reviewEfficacy outcome

    In adults with prediabetes, tirzepatide 15 mg showed potent efficacy in lowering BMI versus placebo.

    In plain wordsIn adults with prediabetes, tirzepatide 15 mg lowered body mass index more than placebo.

    Peptide
    Tirzepatide
    Outcome
    DecreaseBody mass index
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    15 mgAs given in this study (human).

    Source sentences

    Summary
    15 mg of tirzepatide showed significant efficacy in lowering FPG (MD - 9.58 mg/dL; 95% CI - 12.00 to - 7.15), and potent efficacy in lowering BMI.
    2 context sentences
    Summary · context
    Eligible randomized controlled trials (RCTs) enrolled adults with prediabetes, compared the efficacy and safety of placebo and anti-prediabetic drugs (e.g., metformin, sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide-1 receptor agonists, and thiazolidinedione) with a follow-up durati…
    Summary · context
    Fifty-five eligible RCTs involving 37 interventions with 16,610 participants were included in this study.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:07 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.